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Peritoneal dialysis therapy has increased in popularity since the end of the 1970s. This method provides a patient survival
rate equivalent to hemodialysis and better preservation of residual renal function. However, technique failure by peritonitis,
and ultraﬁltration failure, which is a multifactorial complication that can aﬀect up to 40% of patients after 3 years of therapy.
Encapsulant peritoneal sclerosis is an extreme and potentially fatal manifestation. Causes of inﬂammation in peritoneal dialysis
range from traditional factors to those related to chronic kidney disease per se, as well as from the peritoneal dialysis treatment,
including the peritoneal dialysis catheter, dialysis solution, and infectious peritonitis. Peritoneal inﬂammation generated causes
signiﬁcant structural alterations including: thickening and cubic transformation of mesothelial cells, ﬁbrin deposition, ﬁbrous
capsule formation, perivascular bleeding, and interstitial ﬁbrosis. Structural alterations of the peritoneal membrane described
above result in clinical and functional changes. One of these clinical manifestations is ultraﬁltration failure and can occur in up to
30% of patients on PD after ﬁve years of treatment. An understanding of the mechanisms involved in peritoneal inﬂammation is
fundamental to improve patient survival and provide a better quality of life.
1.Introduction
Peritoneal dialysis (PD) therapy has increased in popularity
since the end of the 1970s. The method was developed as
an alternative to hemodialysis (HD) presenting a patient
survival rate equivalent to HD and better preservation of
residual renal function. However, technique failure remains
high, resulting in frequent modality changes. Currently,
the two principal causes of technique failure in order
of importance are (a) peritonitis, this important medical
problemcanalsorepresentnearly16%ofthecausesofdeath;
(b) ultraﬁltration failure, a multifactorial complication that
can aﬀect up to 40% of patients after 3 years of therapy [1].
T h ep e r i t o n e a lm e m b r a n ei sc o m p o s e do fd i ﬀerent cell
types with varying functions. Peritonitis as well as contact
with bioincompatible solutions have deleterious eﬀects on
the membrane. These proinﬂammatory stimuli can induce
lymphokine secretion by macrophages, which in turn,
activate ﬁbroblasts. Fibroblast activation has been associated
with structural alterations in the peritoneal membrane of
varying intensity. These alterations can be seen in Figure 1
which was extracted from a submitted study of our group.
In this prospective controlled study in 20 nonuremic Wistar
rats, peritoneal ﬁbrosis occurs after exposure to glucose-
based PD solutions and regardless the use of simvastatin.
Encapsulant peritoneal sclerosis (EPS) is an extreme and
potentially fatal manifestation. EPS is a clinical syndrome
that leads to persistent or recurrent intestinal obstruction,
with or without inﬂammatory parameters of peritoneal
thickening, sclerosis, calciﬁcation, and encapsulation, and
can be inferred by clinical symptoms and radiology, but
conﬁrmed only by direct visualization with laparotomy
[2, 3]. Incidence of EPS is heterogenous and has been2 Mediators of Inﬂammation
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Figure 1: Typical alterations in the peritoneal membrane in an experimental model of hypertonic dialysate infusion (a) and the impact of
oral statin use during 8 weeks of followup (b).
reported to vary from 6 to 20% in eight years depending on
the region.
2. Causes of Inﬂammation in PD
Causes of inﬂammation in peritoneal dialysis range from
traditional factors to those related to chronic kidney disease
per se as well as from the peritoneal dialysis treatment itself.
UremiaisafactorpresentinallPDpatientsandgenerates
an inﬂammatory state causing stress on the peritoneum
due to the formation of carbonyl products. It accelerates
the formation of advanced glycation end products (AGEs)
that induces an upregulation of the receptors of advanced
glycation end products (RAGE) [4]. Dialysis decreases the
impact of uremia, however, does not remove it completely.
The peritoneal dialysis catheter is the ﬁrst proinﬂam-
matory factor associated to PD with which the patient
comes into contact. After implantation in the peritoneum,
the catheter can induce an inﬂammatory reaction as was
demonstrated by Flessner et al. [5]. In addition, the catheter
can occasionally be the site of bacterial bioﬁlm formation.
Initial therapy introduces the second inﬂammatory
factor associated with PD: dialysis solution. Several PD
solutions are available on the market today, and all are, to
varying degrees, associated with peritoneal inﬂammation.
Such inﬂammation is generated by several characteristics of
these solutions, varying from low pH, presence of lactate,
hyperosmolality, increased glucose concentration, presence
of glucose degradation products (GDP) and advanced gly-
cation end products (AGEs), and icodextrin metabolites,
among others [6, 7].
Currently available glucose-based PD solutions present
concentrations varying between 1.5 and 4.25% of glucose.
The glucose load oﬀered daily by a traditional PD prescrip-
tion usually ranges from 120g to 400g.
The majority of PD solutions prescribed today markedly
acidify pH to nearly 5.7 in approximately 2 to 3 minutes.
This pH decreases viability of neutrophils and mesothelial
cells, thus decreasing cytokine production and phagocytosis
cap-acity. Lactate is utilized as a buﬀer in the majority
of solutions. Its bioincompatibility with the peritoneal
membrane is well known as well as its capacity to stimulate
the production of ﬁbroblast growth factors contributing to
peritoneal ﬁbrosis [8].
The association of icodextrin with EPS development
is controversial. Some studies have associated the osmotic
agent with EPS development [7], while others have shown it
to be distinct, conﬁrming its safety even with long-term uti-
lization [6]. The relative rarity of the disease makes a deﬁni-
tive conclusion diﬃcult. Even experimental studies with rats
addressing this question are compromised by the increased
α-amylase activity in these animals. The presence of this
enzyme in plasma and in the peritoneal cavity provokes a
rapid drop in peritoneal icodextrin concentration [9].
Chronic exposure to high glucose load in traditional PD
solution induces signiﬁcant inﬂammation of the peritoneal
membrane. These solutions induce several proinﬂammatory
factors such as PGA [10], vascular endothelial growth
factors (VEGFs), ﬁbroblast growth factor (TGF-β1), AGEs,
and upregulation of RAGEs. Together, these factors con-
tribute to the occurrence of neoangiogenesis and mesothelial
ﬁbrosis [11]. Glucose degradation products (GDPs), suchMediators of Inﬂammation 3
as methylglyoxal, glyoxal, and 3-deoxyglucosone generated
during the heat sterilization process, increase inﬂammation
by inducing oxidative stress, which thus causes damage to
mesothelial cells and leads to apoptosis and mesothelial
denudation [12].
Substituting traditional solutions for more biocompati-
blesolutionswasrecentlyassociatedwithreducedmembrane
alterations [13]. It has been suggested for some years that
the pathway of transforming growth factor β1/Smad plays a
part in the development of peritoneal ﬁbrosis. High glucose
concentration in PD solutions is related to the activation of
this pathway. The relationship between Smad2 and VEGF
expression has also been reported. The latter is recognized
as playing a role in angiogenesis, a histological characteristic
t h a ta l l o w sf o rd i ﬀerentiation from simple peritoneal ﬁbrosis
to EPS [14].
The endothelial system is another known factor with
potent proﬁbrotic characteristics and plays a role in the
development of peritoneal ﬁbrosis. This system can be
activated by two receptors, endothelial receptors A and B.
However, endothelial receptor B apparently does not play
a role in peritoneal membrane thickening in experimental
studies inducing deﬁciency of endothelial receptor B.
Finally, and of extreme importance, infectious peritonitis
is an obvious cause of peritoneal inﬂammation and is
associated with EPS development. Gram-positive organisms
remain as the more prevalent peritonitis agents over the
past decades representing up to 60% of cases followed
by gram-negative organisms. However, the prevalence of
peritonitis due gram-negative organisms is growing fast with
the development of eﬃc i e n ts t r a t e g i e st oc o n t r o lg r a m -
positive infections. Despite all eﬀorts made over the past
decades, it still represents the most important cause of
treatment discontinuation.
In sum, all the above-mentioned factors contribute to
the release of proinﬂammatory cytokines such as interleukin
1β (IL 1β), tumor necrosis factor (TNF-α), IL-6, and IL-18.
Structural lesions as a result of this process will be addressed
below.
3. Structural Consequences of
Inﬂammation of PD
Peritoneal inﬂammation generated by PD causes signiﬁcant
structural alterations in the peritoneum. These alterations,
when severe, can trigger encapsulant peritoneal sclerosis
[12]. Mesothelial exposure to PD solution in rats increased
cytoplasm in these cells [15]. Thickening and cubic transfor-
mationofmesothelialcellsoccursandismoreaccentuatedin
the parietal peritoneum [16]. Human peritoneal mesothelial
cells (HPMCs) also suﬀer structural alterations and promi-
nent transdiﬀerentiation of HPMC to myoﬁbroblasts occurs
[17].
Histological alterations of the peritoneal membrane
observed in EPS cases are nonspeciﬁc and are masked
by the alterations commonly observed in patients with
ultraﬁltration failure and infectious peritonitis over the long
term [18]. The most common ﬁndings are ﬁbrin deposition,
ﬁbrous capsule formation, perivascular bleeding, interstitial
ﬁbrosis, and the presence of tissue granulation with vascular
proliferation. Submesothelial tissue thickening also occurs
with an increase in deposition of mesothelial conjunctive
tissue [19, 20]. Fibrosis is characterized by the accumulation
of extracellular matrix (ECM), resulting in disequilibrium
between synthesis and degradation. Expression of collagen
types1and3issigniﬁcantlyincreased[21]asw ellasc ollagen
type 4 [10]. Mesothelial cell denudation has also been
described [22].Withrespecttoneoangiogenisis, weobserved
an arteriole diabetiform alteration and subendothelial hyali-
nosis of the venules [23].
4. FunctionalConsequence of
Inﬂammation in PD
Structural alterations of the peritoneal membrane described
above result in clinical and functional changes. One of these
clinical manifestations is ultraﬁltration (UF) failure and can
occur in up to 30% of patients on PD after ﬁve years of
treatment [1]. One of the presentations of UF failure occurs
due to the increase in pores in the peritoneal membrane,
which in turn accelerates small-solute transport dissipating
the osmotic gradient necessary to maintain adequate ﬂuid
balance. This increase in vascular surface is observed in
conjunction with an increase in density of interstitial ﬁbers.
These ﬁndings help justify the increase in transport of
small molecules, while the alterations in the UF coeﬃcient
are only moderate [24]. In addition to UF failure, clinical
manifestations such as severe malnutrition, subocclusion or
intestinal occlusion, and ascites suggest the presence of EPS
even after discontinuation of PD.
Prescribing more hypertonic glucose solutions is a com-
mon strategy to counter this drop in UF, primarily where
there is no available icodextrin. This intensiﬁes and perpet-
uates inﬂammatory disturbances, with a direct impact on
dialysis adequacy and ﬂuid balance. The ﬁnal consequence
is the inevitable transfer to HD. Despite all damage to the
peritoneal membrane with therapies performed today, large
observational studies have shown an important evolution in
PD patient survival when compared to HD over the past
years [25].
5. Conclusion
PD initiation increases inﬂammatory stimuli for the chronic
kidneypatientsuchasthepresenceoftheperitonealcatheter,
use of bioincompatible solutions, and possible infectious
peritonitis. Together, these factors generate structural and
physiological alterations of the peritoneal membrane. These
manifestations are frequently observed and can range from
diﬃculties in obtaining an adequate ﬂuid balance until
the dreaded encapsulant peritoneal sclerosis. Nevertheless,
patient survival in PD is similar to that of HD. An
understanding of the mechanisms involved in peritoneal
inﬂammation is fundamental for the development of new
strategies. This knowledge can provide not only a better
techniquesurvival,butalsoimprovementsinpatientsurvival
and a better quality of life.4 Mediators of Inﬂammation
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